Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company [Yahoo! Finance]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
51% of the business is held by the top 8 shareholders Insiders have been selling lately AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To get a sense of who is truly in control of Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ), it is important to understand the ownership structure of the business. We can see that institutions own the lion's share in the company with 70% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future. Let's take a closer look to see what the different types o
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Non-Viral Gene Delivery Technologies Market Size to Hit USD 9.57 Billion by 2033, Growing at a CAGR of 12.55% - SNS Insider [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Piper Sandler from $70.00 to $100.00. They now have an "overweight" rating on the stock.MarketBeat
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Business Wire
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Royal Bank Of Canada from $52.00 to $80.00. They now have an "outperform" rating on the stock.MarketBeat
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Bank of America Corporation from $62.00 to $81.00. They now have a "buy" rating on the stock.MarketBeat
ARWR
Earnings
- 11/25/25 - Miss
ARWR
Sec Filings
- 12/19/25 - Form 4
- 12/19/25 - Form 144
- 12/19/25 - Form 144
- ARWR's page on the SEC website